Andrew Balo

2015

In 2015, Andrew Balo earned a total compensation of $3.5M as EVP, Clinical, Regulatory and Quality at DexCom.

Compensation breakdown

Non-Equity Incentive Plan$379,266
Salary$310,000
Stock Awards$2,830,478
Other$22,524
Total$3,542,268

Balo received $2.8M in stock awards, accounting for 80% of the total pay in 2015.

Balo also received $379.3K in non-equity incentive plan, $310K in salary and $22.5K in other compensation.

Rankings

In 2015, Andrew Balo's compensation ranked 2,559th out of 13,638 executives tracked by ExecPay. In other words, Balo earned more than 81.2% of executives.

ClassificationRankingPercentile
All
2,559
out of 13,638
81st
Division
Manufacturing
902
out of 5,187
83rd
Major group
Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And Optical Goods; Watches And Clocks
108
out of 754
86th
Industry group
Surgical, Medical, And Dental Instruments And Supplies
62
out of 460
87th
Industry
Surgical and Medical Instruments and Apparatus
34
out of 287
88th
Source: SEC filing on April 6, 2016.

Balo's colleagues

We found four more compensation records of executives who worked with Andrew Balo at DexCom in 2015.

2015

Kevin Sayer

DexCom

Chief Executive Officer

2015

Richard Doubleday

DexCom

EVP, Chief Commercial Officer

2015

Steven Pacelli

DexCom

EVP-Strategy and Corporate Development

2015

Jess Roper

DexCom

Chief Financial Officer

News

You may also like